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Copyright © 2009 JCBN Summary In clinical trials for dietary supplements and functional foods, the study population
tends to be a mixture of healthy subjects and those who are not so healthy but are not
definitely diseased (called “borderline subjects”). For such heterogeneous populations, the t-
test and ANCOVA method often fail to provide the desired treatment efficacy. We propose an
alternative approach for the efficacy evaluation of dietary supplements and functional foods
based on a change-point linear regression model. The model does not require the assumption
of a constant treatment effect and provides clinically interpretable results. By employing the
AIC-based profile likelihood method, inferences can be made easily using standard statistical
software. The proposed method was applied to the Garcinia study data, and the merit of the
method was demonstrated by comparing it with traditional methods.
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Introduction
Dietary supplements and functional foods have been
popular and are widely used. Just as with drugs, the efficacy
and safety of dietary supplements and functional foods
should be evaluated from a scientific viewpoint. One of
the most desirable ways is to evaluate them based on data
from randomized clinical trials. Various approaches such as
randomization procedures, blinding and so on which are
used in evaluating drugs in addition to most statistical
methods that are used in drug development are quite useful
for evaluating dietary supplements and functional foods.
Among these approaches, the t-test and the analysis of
covariance method (ANCOVA) are often applied for the
efficacy evaluation of dietary supplements and functional
foods.
Nagano et al. [1] and Tsuji et al. [2] applied the t-test in
evaluating the efficacy, respectively, of diacylglycerol and
medium-chain triacylglycerols in anti-obesity remedies; the
change from a baseline for obesity-related parameters such
as visceral fat area (VFA), body weight and body mass index
were compared between two experimental groups. Nagano
et al. [1] also applied ANCOVA for testing the decreasing
effect of diacylglycerol on VFA. In these papers, the t test
and ANCOVA were successfully applied, indicating the
usefulness of these methods for evaluating dietary supple-
ments and functional foods. However, these methods assume
the effect of constant treatment on a study population. While
an experimental drug may be expected to be effective
regardless of baseline observations, this is not always true in
evaluating dietary supplements and functional foods. The
main reason for this difference is the fact that when a
mixture of healthy subjects and those who not so healthy but
not definitely diseased (called “borderline “subjects) are
enrolled in a study, the magnitude of the efficacy amongK. Hayamizu et al.
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healthy subjects tends to be less than that with borderline
subjects. This heterogeneity may cause a loss in the effective-
ness of t tests and ANCOVA, and therefore the estimate of
the treatment effect by assuming a homogenous study popu-
lation may be misleading.
In this article, we propose an alternative approach to the
t test and ANCOVA for evaluating dietary supplements and
functional foods. Our method is based on a change-point
linear regression, which does not require the assumption of a
constant treatment effect. Our method assumes that the treat-
ment effect is zero for subjects whose baseline value are less
than the change-point and varies monotonically as the
baseline value more than the change-point increase. Thus the
change-point has a good interpretation that subjects with
baseline value more than the change-point is potential
candidate to have a benefit. We present a method to estimate
regression parameters in a change-point regression analysis
and propose a way to determine the change-point based on
Akaike Information Criterion (AIC) based profile likelihood
approach.
Materials and Methods
Suppose we are interested in analyzing data from a
randomized and controlled clinical trial of dietary supple-
ments or functional foods which was conducted under what
is called pre-post design. More precisely, we consider a
two-armed comparative study consisting of a control arm
and an experimental arm with the endpoint being measured
at the baseline and at the study’s end. Since the study end-
point may be strongly influenced by the values measured at
the baseline, the treatment effect may depend on the level of
baseline values shown in Fig. 1 (Panel A).
We propose the following regression model, which takes
into account differential baseline effects:
yi = β0 + β1xi + β2I (xi>xcp)(xi – xcp) gi + εi (i = 1, 2, 3, …, n)
(Eq 1)
where n is the number of subjects, yi is the observation at the
study’s end of subject i, xi is the observation at the baseline
of subject i, xcp is a constant, gi is the group indicator (control;
0, treatment; 1) and I (·) is an indicator function defined as I
(xi>xcp) = 1 if xi>xcp and 0 is otherwise.
The regression lines for the two groups are the same for xi
less than xcp and different for xi equal to or more than xcp.
Then xcp is regarded as a change-point of the relationship of
observations at the baseline and those at the study’s end; we
call this model the change-point regression model (CPRM).
If the CPRM fits the data well, and β2 is not equal to zero,
the treatment is effective for subjects with observations at
baseline greater than xcp. Thus, xcp is a useful indicator of
whether the treatment provides benefits.
To estimate the regression coefficients and the change-
point, we employ the maximum profile likelihood approach.
For a fixed xcp, the CPRM is regarded as a special case of
ordinal linear regression models. This implies that the
regression coefficients can be easily estimated by the
standard maximum likelihood methods for linear regression
models and that one can obtain estimators with any standard
software package which can handle linear regression
models. We propose to apply the CPRM with various
change-points xcp and select the optimal change-point by
using AIC:
AIC = −2 maximum log-likelihood +2 p, where p is the
number of unknown parameters of the model [3]. We select
Fig. 1. Fitted regression lines for three models. Each panel shows measurements of subjects in the placebo (open circle) and the
experimental groups (closed circle) with regression lines for the placebo (dashed line) and experimental groups (solid line).
Regression lines in Panel A are by the Change-point regression model (Eq 1), those in Panel B are by ANCOVA (Eq 2) and
those in Panel C are by ANCOVA with interaction (Eq 3).Change-point Regression Model
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the model which minimizes AIC among candidate models.
The ANCOVA models
yi = β0 + β1xi + β2gi + εi (i = 1, 2, 3, …, n) (Eq 2)
or
yi = β0 + β1xi + β2gi + β3xi*gi + εi (i = 1, 2, 3, …, n)(Eq 3)
are often applied to dietary supplements and functional
foods data. The ANCOVA model (Eq 2) assumes that the
effect of the treatment is homogenous over entire baseline
observations and may be less appropriate for dietary
supplements and functional foods data since healthy subjects
may be influenced by the treatment (Fig. 1, Panel B). The
ANCOVA model (Eq 3) has an interaction term that makes
it impossible to summarize the effect of the treatment in a
simple way (Fig. 1, Panel C). A frequently used t-test for
measurement at the study’s end minus the baseline value is
represented as
yi – xi = β0 + β1gi + εi (i = 1, 2, 3, …, n) (Eq 4)
, which becomes a special case of (Eq 2) by setting β1 =1 .
Thus, ANCOVA adjusts the baseline more flexibly. AIC
enables us to compare these analyses of the covariance
models and the CPRM.
Application data
Garcinia (Garcinia cambogia), a plant native to South-
eastern Asia, includes (−)-hydroxycitric acid [4]. HC (−)-
HCA is has been shown to inhibit ATP-citrate lyase,
blocking the conversion of citrate to acetyl-CoA, the first
step in fatty acid synthesis [5]. Recently, Garcinia extracts
containing HCA have been commonly marketed as dietary
supplements for weight management [6–9].
We consider two anti-obesity studies of Garcinia [10, 11].
Both studies were double-blind, placebo-controlled trials
conducted in Japan in which the efficacy was evaluated by
VFA at the study’s end. The first study (called Study 1) was
conducted to evaluate the efficacy and safety of Garcinia for
subjects with Class 1 Obesity (BMI, 25–35 kg/m2). Note that
in Study 1, VFA was not accounted for as inclusion criteria.
The average of VFA at the baseline was 83.0 cm2 (range;
26.2–143.0 cm2). There were no differences between the two
groups, but there was higher VFA in the subjects who had an
initial VFA that was >90 cm2, the VFA in the Garcinia-
treated group significantly decreased compared to placebo
group [10].
The other study (called Study 2) was conducted to evaluate
the efficacy and safety of Garcinia for subjects with a higher
VFA at the baseline. In Study 2, VFA was used to define
inclusion criteria; subjects with VFA greater than 90 cm2
were enrolled. The average of VFA at the baseline
was145.5 cm2 (range; 90.4–244.3 cm2), and the Garcinia
group had a significantly reduced VFA (without subgroup
analysis) [11]. Details of Studies 1 and 2 are summarized in
Table 1.
Except for the inclusion criteria regarding VFA, Studies 1
and 2 were conducted under a similar study procedure. In
both studies, VFA at the study’s end was strongly influenced
by that at the baseline. With the pooled dataset from Studies
1 and 2 (which included subjects with wider VFA at the
baseline), we evaluated the efficacy of Garcinia with regard
to VFA at the baseline. The relationship between VFA at the
baseline and that at the study’s end was expected to be
examined more precisely with the pooled dataset. Thus, we
applied CPRM, which we proposed, to the pooled dataset in
order to evaluate whether Garcinia is effective or not and
with what VFA at the baseline subjects would be expected to
respond to Garcinia.
Results
Fig. 2 (Panel A) shows AICs for various change-point
regression models in the Garcinia study. The model with the
change-point of 62.4 cm2 has minimum AIC among the
CPRM and therefore is the most preferable. In Table 2, AICs
for the linear regression model with only a group indicator
as explanatory variables (t-test) and the ANCOVA model
(Eq 2) and (Eq 3), as well as CPRM with the change-point
of 62.4 cm2, are presented. Table 2 indicates that the CPRM
fits better than the ANCOVA models. Thus, we selected
the change-point regression model with the change-point of
62.4 cm2 as the final model.
Estimated regression coefficients are presented in Table 3.
Table 1. Summary of Garcinia studies
Study design Subject diagnosis Number of subject
Dosage in mg/day 
(duration)
VFA at baseline 
(range) (cm2)
Study 1 Randomized, placebo-
controlled, double-blind
Overweight 40 
(20 male, 20 female)
1000 mg (−)-HCA 
(8 weeks)
83.0 
(26.2–143.0)
Study 2 Randomized, placebo-
controlled, double-blind
Overweight 
or obese
39 
(18 male, 21 female)
1000 mg (−)-HCA 
(12 weeks)
145.5 
(90.4–244.3)K. Hayamizu et al.
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The interaction term is statistically significantly for values
far from 0 (p<0.0001). It indicates that the CPRM fits well
with the data. For values below 62.4, both groups showed
the same slope (1.10506), meaning that for subjects with
baseline measurement less than 62.4 cm2 the placebo and
Garcinia groups did not change from their baseline measure-
ments (Fig. 2, Panel B). For values over 62.4, only for the
placebo groups did the slope not change. The slope of the
Garcinia group declined to 0.78292, a decrease of approxi-
mately 32% compared to that of the placebo groups. This
result implies that Garcinia is effective for subjects with
baseline measurements greater than 62.4 cm2 and that the
magnitude of its effectiveness is proportional to the baseline
measurements.
Discussion
In the nutrient field, CPRM has already been applied in
previous studies. For example, Marini et al. applied it in vivo
urea kinetic studies [12]. Other examples can be found in
studies on amino acid in animal or human subjects [12–16].
Here CPRM was used to estimate nutrient requirements.
Robbins et al. reported the growth response of young chicks
to graded additions of L-histidine; they used CPRM (they
called it the “broken-line model”) to estimate the L-histidine
requirement [13]. Zello et al. used CPRM (they called it
the “two-phase linear regression model”) and reported the
dietary lysine requirement of young adult males by oxida-
tion of L-[1-13C] phenylalanine [14].
In this paper, we proposed the use of CPRM to evaluate
the efficacy of dietary supplements and functional foods
data, especially in a two-armed comparative study. The
CPRM is a natural approach for dietary supplements and
functional foods in the sense that since these are used by
both healthy people and “borderline” people, their efficacy
may not be homogeneous among this entire population. We
think that desirable dietary supplements have efficacy in
mild ways and are unable to bring about a change that is
equal to maintaining the body condition of healthy men.
Their efficacy can be examined by applying CPRM and
checking whether the change-point is within the normal
range of the endpoint at the baseline.
Fig. 2. Result of Change-point regression model (CPRM) for Garcinia study (combined data). The open and closed circles mean
placebo and treatment groups, respectively. Panel A is profile of AICs of CPRM with a change point of xcp: minimum AIC is
attained at xcp is 62.4 (cm2). Panel B is Scatter plot of VFA at the study end versus Pre-VFA with regression lines for placebo
(dashed line) and experimental groups (solid line) by CPRM with a change-point of 62.4 cm2 in Garcinia study: the treatment
group was effective only for subjects with Pre-VFA greater than 62.4 cm2.
Table 2. AIC of CPRM and ANCOVA models for Gracinia
study
Model AIC
CPRM with xcp of 62.4 (Eq 1) 667.184
ANCOVA (Eq 2) 685.930
ANCOVA with interaction (Eq 3) 667.605
T-test (Eq 4) 684.969
Table 3. ANOVA table of CPRM with xcp of 62.4 in Garcinia study
Estimate Coefficient SE t value p value
β0 −6.884 4.827 −1.426 0.158
β1 1.105 0.044 25.032 <0.0001
β2 −0.322 0.051 −6.262 <0.0001Change-point Regression Model
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While there are estimation methods available to estimate
the change-point directly [17], they are quite complicated.
We employed the profile likelihood approach and proposed
using AIC to determine the change-point. The AIC-based
profile likelihood approach is much simpler and can be
easily conducted by any standard statistical software that can
handle multiple regression models. Thus, our method has
great potential for wide use in practice. In addition, CPRM
also can provide onset information about the effects of the
xcp value. This information cannot be provided by
ANCOVA,  t-test and other usual methods, and its great
usefulness in planning future studies provides a further
advantage for CPRM.
We mention the range of the change-points that are
provided by the AIC. In Fig. 3 (Panel A), profiles of AICs
are shown that were obtained by applying our method only
to Study 1. Recall that the range of VFA at the baseline was
26.2–143.0 (cm2), which was much narrower than that for
the combined data. AIC profiles for the change-points
shown in Fig. 3 (Panel A) have an unusual profile with two
minimals. The minimal around 120 cm2 may be due to a
sample size that was too small for a baseline VFA greater
than 120 cm2; in Study 1 there were only 8 subjects in both
groups with such a baseline VFA. Thus, when CPRM is
applied, subjects with baseline observations ranging
sufficiently wide should be enrolled. The models with the
change-points near the boundary should be excluded from
candidate models. In other words, the range of the change-
points should be determined in advance of the model selec-
tion. Future research should examine how to determine this
range.
Finally we provide an interpretation of CPRM as a
varying-coefficient model [18]. Consider a varying-
coefficient model defined as
yi = γ0 + γ1xi + γ2 (xi)gi + εi (i = 1, 2, 3, …, n) (Eq 5)
, where γ2 (xi) is a function of xi, representing the covariate-
varying treatment effect. When γ2 (xi)=β2, (Eq 4) reduces to
ANCOVA (Eq 2) and when γ2 (xi)=β2 + β3xi, it reduces to
(Eq 3). CPRM corresponds to γ2 (xi)=β2I (xi>xcp)(xi – xcp).
This is one of the simplest forms of the covariate –varying
treatment effect and has a nice interpretation. By applying
spline-based regression models or local-polynomial regres-
sion techniques, one can handle the varying coefficient
models with general functions γ2 (xi). However, in clinical
trials for dietary supplements and functional foods, sample
size is not always large, and simpler statistical models are
preferable. Thus, our approach is especially attractive when
the sample size is not necessarily large.
Conclusion
We propose an alternative approach for the efficacy
evaluation of dietary supplements and functional foods
based on a change-point linear regression model. By
employing the AIC-based profile likelihood method, infer-
ences can be made easily using standard statistical software.
The proposed method was applied to the Garcinia study
data, and the merit of the method was demonstrated by
comparing it with the ANCOVA models.
Abbreviations
AIC, Akaike information criterion; ANCOVA, analysis of
covariance method; CPRM, change-point regression model;
VFA, visceral fat area.
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